Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Rigosertib sodium by Traws Pharma for Non-Small Cell Lung Cancer: Likelihood of Approval
Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Non-Small Cell Lung Cancer. According...
Rigosertib sodium by Traws Pharma for Lung Adenocarcinoma: Likelihood of Approval
Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Lung Adenocarcinoma. According to GlobalData,...
Rigosertib sodium by Traws Pharma for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Squamous Non-Small Cell Lung Cancer....
Rigosertib sodium by Traws Pharma for Squamous Cell Carcinoma: Likelihood of Approval
Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Squamous Cell Carcinoma. According to...
Rigosertib sodium by Traws Pharma for Epidermolysis Bullosa: Likelihood of Approval
Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Epidermolysis Bullosa. According to GlobalData,...